Vildagliptin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Vildagliptin: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome
One-Sentence Summary
Vildagliptin is an oral DPP-4 inhibitor originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for focal stiff limb syndrome, but no clinical trials and no publications currently support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus |
| Predicted New Indication | Focal stiff limb syndrome |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Target data show that vildagliptin binds dipeptidyl peptidase 4 (DPP-4), with activity also recorded against DPP-8, DPP-9 and TRPV4. Blocking DPP-4 raises active GLP-1 and GIP levels and lowers glucagon, which improves glycaemic control in type 2 diabetes.
Focal stiff limb syndrome is a rare neurological condition within the stiff-person spectrum. These disorders are usually linked to GABAergic dysfunction and autoimmunity (often anti-GAD65 antibodies). No mechanistic link between DPP-4 inhibition and this pathology is supported by the available data.
The very high score (99.88%) is a model output only. It most likely reflects proximity in the knowledge graph, such as shared links to diabetes and autoimmune-related biology, rather than demonstrated biology. A closely related prediction, classic stiff person syndrome, received the same score and also has no supporting evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN13407P | Galvus Tablet 50mg | Tablet |
| SIN13685P | Galvus Met Tablet 50mg/850mg | Film-coated tablet |
| SIN13684P | Galvus Met Tablet 50mg/1000mg | Film-coated tablet |
| SIN13952P | Galvus Met Tablet 50mg/500mg | Film-coated tablet |
All four registrations are currently valid. All are oral products (three are vildagliptin/metformin combinations).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical or literature support, no plausible mechanistic link, and an evidence level of L5. Advancing it would be speculative.
To proceed, the following is needed:
- A credible mechanistic hypothesis linking DPP-4 inhibition (or vildagliptin's other targets) to stiff limb or stiff-person pathology
- Preclinical or case-level evidence in this condition
- Complete mechanism-of-action data and the package insert warnings and contraindications
- Review of other lower-ranked predictions: type 1 diabetes mellitus, for example, has Phase 2 to 4 trials and an RCT. It is a separate candidate and would need its own assessment.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.